F1J-MC-HMFN (a) An Open-Label Study of Tolerability, Safety, and Pharmacokinetics of Duloxetine in the Treatment of Children and Adolescents With Major Depressive Disorder.

Trial Profile

F1J-MC-HMFN (a) An Open-Label Study of Tolerability, Safety, and Pharmacokinetics of Duloxetine in the Treatment of Children and Adolescents With Major Depressive Disorder.

Completed
Phase of Trial: Phase II

Latest Information Update: 06 Mar 2017

At a glance

  • Drugs Duloxetine (Primary)
  • Indications Major depressive disorder
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Eli Lilly
  • Most Recent Events

    • 19 Nov 2008 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 01 Oct 2008 Primary outcomes amended as reported by CT.gov
    • 01 Oct 2008 Planned end date changed from 1 Dec 2008 to 1 Sep 2008 as reported by CT.gov
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top